Grow with Ginkgo Q1 2025 Update & Business Review May 6, 2025 Property of Ginkgo Bioworks — 1 Q1 2025 UPDATE & BUSINESS REVIEW Disclaimer FORWARD-LOOKING STATEMENTS This presentation, the conference call and webcast contain certain forward-looking statements within the meaning of the federal securities laws, including statements regarding our plans, strategies, including with respect to our current expectations, operations and anticipated results of operations, both business and financial, including the tim ...

Ginkgo Bioworks Holdings, Inc. (DNA) came out with a quarterly loss of $1.58 per share versus the Zacks Consensus Estimate of a loss of $1.23. This compares to loss of $3.20 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -28.46%. A quarter ago, it was expected that this company would post a loss of $1.45 per share when it actually produced a loss of $1.82, delivering a surprise of -25.52%.Over the last four quarters, the comp ...

Ginkgo Bioworks (DNA) Q1 2025 Earnings Call May 06, 2025 05:30 PM ET Speaker0 Communications and ownership. It's my third year here at Ginkgo. I've spent much of that time working behind the scenes with our investor relations team on these earnings calls, but I'm thrilled to be joining you for the first time live on air. I'm joined by Jason Kelly, our cofounder and CEO, and Mark Demetriuk, our CFO. Thanks as always for joining us. We're looking forward to updating you on our progress. As a reminder, during ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q ______________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________________ to _________________ Commission File Number: 001-40097 ______________________ ...

Revenue Performance - Total revenue for Q1 2025 was $48 million, a 27% increase from $38 million in the same period last year, primarily due to a $7 million non-cash revenue release[6]. - Cell Engineering revenue for Q1 2025 was $31 million, up 10% from $28 million in the prior year, driven by growth with biopharma and government customers[6]. - Cell Engineering revenue increased to $38,230,000 in Q1 2025 from $27,889,000 in Q1 2024, representing a growth of 37.5%[19]. - Total revenue for Q1 2025 was $48,318,000, up from $37,944,000 in Q1 2024, marking a 27.5% increase[19]. - Full year 2025 revenue guidance updated to $167-$187 million, with Cell Engineering revenue projected at $117-$137 million[12]. Financial Losses and Improvements - GAAP net loss for Q1 2025 was $(91) million, an improvement from $(166) million in the same period last year[6]. - Net loss narrowed to $90,957,000 in Q1 2025 compared to a net loss of $165,911,000 in Q1 2024, improving by 45.0%[19]. - Basic net loss per share improved to $(1.68) in Q1 2025 from $(3.31) in Q1 2024[19]. - Adjusted EBITDA for Q1 2025 was $(47) million, an improvement from $(117) million in the prior year, attributed to increased revenue and decreased operating expenses[6]. - Adjusted EBITDA for Q1 2025 was $(47,451,000), an improvement from $(117,001,000) in Q1 2024[29]. - The total segment operating loss for Q1 2025 was $(36,773,000), compared to $(103,471,000) in Q1 2024, reflecting a significant reduction in losses[25]. Cost Management - The company aims to achieve $250 million in annualized cost reductions by the end of Q3 2025, with a current run-rate cost reduction of $205 million[6]. - Research and development expenses decreased to $70,923,000 in Q1 2025 from $136,457,000 in Q1 2024, a reduction of 48.0%[19]. - Total operating expenses decreased to $137,286,000 in Q1 2025 from $215,946,000 in Q1 2024, a decline of 36.4%[19]. - The company incurred restructuring charges of $5,273,000 in Q1 2025, primarily related to employee termination costs[26]. Cash and Backlog - Cash, cash equivalents, and marketable securities as of March 31, 2025, totaled $517 million[6]. - Cash and cash equivalents at the end of Q1 2025 were $312,420,000, down from $840,440,000 at the end of Q1 2024[23]. - Ginkgo has a contracted backlog of approximately $180 million across 28 US Government projects in Cell Engineering and Biosecurity[6]. Market Position and Growth - Ginkgo's Datapoints and Automation offerings are gaining traction, including a new deal with Aura Genetics, marking its first diagnostics company customer[6]. - The company is well-positioned in the biotechnology sector, which is emphasized as a critical area of national importance by US government reports[6].

Core Insights - Ginkgo Bioworks has made significant progress in its restructuring efforts, targeting $250 million in cost savings by Q3 2025 [1][3][7] - The company reported a total revenue of $48 million for Q1 2025, a 27% increase from $38 million in the same period last year, primarily due to a $7 million non-cash revenue release [6][22] - Ginkgo's Solutions business is becoming a trusted R&D service provider for the US Government and biopharma industry, while its Tools business is gaining traction in AI-related opportunities [3][7] Financial Performance - Q1 2025 total revenue was $48 million, with $31 million from Cell Engineering (up 10% year-over-year) and $10 million from Biosecurity (flat year-over-year) [6][22] - The company reported a GAAP net loss of $91 million for Q1 2025, an improvement from a net loss of $166 million in the prior year [6][22] - Adjusted EBITDA for Q1 2025 was $(47) million, an improvement from $(117) million in the prior year, driven by increased revenue and reduced operating expenses [6][22] Strategic Positioning - Ginkgo is well-positioned in the biotechnology sector, with 28 US Government projects and a contracted backlog of approximately $180 million [7] - The company is focusing on biosecurity and R&D services, which are deemed critical by national policy reports [7] - Ginkgo's Datapoints and Automation offerings are generating new deals, including a recent agreement with Aura Genetics [7] Guidance and Outlook - Ginkgo has updated its 2025 guidance to reflect total revenue expectations of $160-$180 million, with Cell Engineering revenue projected at $110-$130 million and Biosecurity revenue at least $50 million [5][13] - The company aims to achieve Adjusted EBITDA breakeven by the end of 2026 [7]

Replacing artificial dyes with natural colors has become a national priority, moved by consumer demand, regulation, and governmental pressure. Achieving this milestone—by increasing coloring efficiency and reducing costs—could unlock new market segments that are not well-supported by current natural food colors. The achievement grants Ginkgo with additional equity in Phytolon, and paves the way to explore further collaborations in the field of natural food colors.YOKNE'AM ILLIT, Israel and BOSTON, April 30 ...

Presentation and Q&A session scheduled for post-market on Tuesday, May 6, 2025 BOSTON, April 29, 2025 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo"), which is building the leading platform for cell programming and biosecurity, today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2025, on Tuesday, May 6, 2025, beginning at 5:30 p.m. ET. The presentation details and webcast link will be available on Gink ...

Ginkgo Bioworks Holdings, Inc. (DNA) closed at $7.60 in the latest trading session, marking a +0.8% move from the prior day. The stock trailed the S&P 500, which registered a daily gain of 1.67%. On the other hand, the Dow registered a gain of 1.07%, and the technology-centric Nasdaq increased by 2.5%.Coming into today, shares of the company had gained 5.9% in the past month. In that same time, the Medical sector lost 9.34%, while the S&P 500 lost 6.57%.The upcoming earnings release of Ginkgo Bioworks Holdi ...

Exclusive: As genetic testing company 23andMe seeks to sell the consumer data of millions of Americans as part of its bankruptcy proceedings, Senate HELP Committee Chairman Bill Cassidy is opening up a probe into the company to ensure that users' medical data and DNA do not fall into the wrong hands. In a pair of letters obtained by FOX Business, Cassidy, R-La., raised concerns with Treasury Secretary Scott Bessent and 23andMe executives over the risk that Chinese companies or other foreign adversaries may ...